Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in relapsed or refractory germ-cell tumors
NCT01743482Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in germ cell tumor (GCT), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started May 2013; status: completed.
02
Drugs
pazopanib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT01743482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743482.